You may have to Search all our reviewed books and magazines, click the sign up button below to create a free account.
New technologies with the potential to improve the health of populations are continuously being introduced. But not every technological development results in clear health gains. Health technology assessment provides evidence-based information on the coverage and usage of health technologies, enabling them to be evaluated properly and applied to health care efficaciously, promoting the most effective ones while also taking into account organizational, societal and ethical issues. This book reviews the relationship between health technology assessment and policy-making, and examines how to increase the contribution such research makes to policy- and decision-making processes. By communicating the value and potential of health technology assessment to a wider audience, both within and beyond decision-making and health care management, it aims ultimately to contribute to improve the health status of the population through the delivery of optimum health services.
This volume was first published by Inter-Disciplinary Press in 2013. Chronic illness, together with people experiencing or treating it, became almost mute to predominant biomedical narration pervasive in mainstream media, education, medical and pharmaceutical industry. Contributors in this book aim to represent, discuss, and preserve the vanishing voices and stories on chronic illness from dimensions beyond medicine so that we may make sense of chronicity with the diversity it deserves. The book also incorporates research articles which share important stories about chronicity. These stories, same as chronic illness in our world, should not be treated in a ‘standardised’ way. Each reader, we hope, will relate the meanings of chronicity in this book to his or her own world.
A necessary book for healthcare professionals and theologians struggling with moral questions about rationing in healthcare. This book outlines a Christian ethical basis for how decisions about health care funding and priority-setting ought to be made.
Almost half a century ago, policy leaders issued the Declaration of Alma Ata and embraced the promise of health for all through primary health care (PHC). That vision has inspired generations. Countries throughout the world—rich and poor—have struggled to build health systems anchored in strong PHC where they were needed most. The world has waited long enough for high-performing PHC to become more than an aspiration; it is now time to deliver. The COVID-19 (Coronavirus) pandemic has facilitated the reckoning for that shared failure—but it has also created a once-in-a-generation opportunity for transformational health system changes. The pandemic has shown policy makers and ordinary cit...
Chronic conditions and diseases are the leading cause of mortality and morbidity in Europe, accounting for 86% of total premature deaths, and research suggests that complex conditions such as diabetes and depression will impose an even greater health burden in the future - and not only for the rich and elderly in high-income countries, but increasingly for the poor as well as low- and middle-income countries. The epidemiologic and economic analyses in the first part of the book suggest that policy-makers should make chronic disease a priority. This book highlights the issues and focuses on the strategies and interventions that policy-makers have at their disposal to tackle this increasing ch...
Analyses the relation of preventive and curative health policy and its evolution over time.
Im Arzneiverordnungs-Report werden seit 1985 Daten, Kosten und Analysen zur Verordnung von Arzneimitteln für die Patienten der gesetzlichen Krankenversicherung (GKV) publiziert. Datenbasis des Jahres 2018 sind 800 Millionen Verordnungen von 147.713 Vertragsärzten und 65.513 Vertragszahnärzten für 72,997 Mio. GKV-Versicherte. Die allgemeine Verordnungs- und Marktentwicklung wird in 8 Kapiteln dargestellt, in denen zusätzlich europäische Zulassungsverfahren, 37 neue Arzneimittel des Jahres 2018, Biologika und Biosimilars, Orphan-Arzneimittel, Ergebnisse des AMNOG-Erstattungsbetragsverfahrens und europäische Arzneimittelpreise thematisiert werden. Die speziellen Verordnungsdaten der 3000 meistverordneten Arzneimittel (Markterfassung 98%) werden in 39 Kapiteln über die führenden Indikationsgruppen evidenzbasiert analysiert. Aus dem Inhalt Allgemeine Verordnungs- und Marktentwicklung Indikationsgruppen Ergänzende statistische Übersicht
Im seit 1985 als Buch erscheinenden Arzneiverordnungs-Report werden die Rezepte für die Patienten der gesetzlichen Krankenversicherung (GKV) mit Methoden der evidenzbasierten Medizin analysiert.Seit dieser Zeit bietet der Report eine unabhängige Informationsmöglichkeit über die verschiedenen Komponenten der Arzneimittelverordnung und trägt damit zur Transparenz des Arzneimittelmarkts, zur Bewertung von Arzneimitteln und zu einer sowohl zweckmäßigen und sicheren evidenzbasierten als auch wirtschaftlichen Arzneitherapie bei. Die etablierte Gliederung des Arzneiverordnungs-Reports in vier Teilabschnitte wurde im neuen, größeren Buchformat beibehalten. Darüber hinaus werden weitere Komponenten des Arzneimittelmarkts in vier neuen Kapiteln über Zulassungsverfahren für neue Arzneimittel in Europa, das AMNOG-Erstattungsbetragsverfahren, Arzneimittelrabattverträge und einen europäischen Preisvergleich für patentgeschützte Arzneimittel dargestellt.
"The second issue of Health Policy Developments takes a closer look at three topics high on the health policy agenda in most industrialized countries. It concentrates on the health policy challenges typical of an aging society, on recent developments in pharmaceutical policy and on changes in human resources policies to cope with shortages of medical professionals."--BOOK JACKET.